Oncology Central

ESMO18: Olaparib maintenance improves progression-free survival in advanced ovarian cancer by 3 years

0
SOLO-1 is the first, double-blind, randomized, prospective Phase III trial to evaluate front-line olaparib maintenance therapy after platinum-based chemotherapy in newly diagnosed advanced ovarian cancer with BRCA mutation.

In total, the study included 391 patients with high grade serous or endometrioid ovarian cancer who were in clinical complete or partial response after chemotherapy. The patients were randomized, 2:1, to olaparib tablets (n=260) or placebo (n=131) for 2 years.

The primary endpoint was investigator-assessed progression-free survival (PFS) from randomization. Median follow-up was 41 months.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.